Azenta Expands DNA Synthesis Portfolio With SynPlexity Acquisition and Elegen License

What happened

On October 28, 2026, Azenta acquired SynPlexity and signed two Elegen agreements to expand its DNA synthesis capabilities. The Elegen license is exclusive and royalty-free for five years, with an option to pay $25 million for perpetual rights.

Confirmed

Global impact / market context

Azenta is spending to build in-house DNA synthesis capacity rather than only relying on partners. The expected $32 million to $71 million deployment ties up cash, but wider gene synthesis offerings could lift revenue from its GENEWIZ services and support regional production.

Analyst inference

Life-science tools providers are adding gene synthesis capabilities as research demand grows. This deal mixes an acquisition with licensing and supply contracts, so Azenta gains technology and consumables access together, while the optional $25 million payment makes part of its spending conditional.

Analyst inference

What to watch

1. Azenta expects total capital deployment of about $32 million to $71 million for the Elegen arrangements, depending on equipment purchases and whether it exercises the $25 million perpetual license option. Confirmed
2. Investors could track whether Azenta exercises the option to pay $25 million plus unpaid fees for permanent exclusive rights, which would move spending toward the top of its expected range. Proposed
3. Watch whether the acquired SynPlexity technology and licensed Elegen platform add gene synthesis revenue through GENEWIZ and regional production, and whether consumables and service costs weigh on profit per sale. Analyst inference

Evidence

• Original source link unavailable